AI Consensus Investment Thesis
Amgen (AMGN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$399
+3.5%+5.8% incl. dividends5-Year
NEUTRAL$512
+32.8%+48.0% incl. dividendsLatest flagship insight
Biotech Giant Balances Looming Patent Cliffs Against High Margin Pipeline Renewal
Analysis reveals high consensus that commercial expansion across core growth pillars and over ten billion dollars in free cash flow absorb severe denosumab patent erosion. However, sharp divergence persists regarding whether pipeline assets can overcome elevated balance-sheet debt and high-rate valuation compression.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Michael Burry (Vulture), J.P. Morgan (Titan), Elon Musk (Visionary), Machiavelli (Insider), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Amgen at the forecast anchor (2026-09-18): $14,805 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.2% net dividend yield for Amgen.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 386.58 | +0.24% | +0.24% | Volume growth across cardiovascular and rare-disease portfolios absorbs initial denosumab biosimilar discounting. However, persistent five percent Treasury yields and high refinancing costs constrain broad equity multiple expansion, maintaining range-bound valuation consolidation. |
| Q1 2027 | 385.93 | -0.17% | +0.07% | Statutory Medicare price resets take effect on mature blockbusters while denosumab erosion accelerates in domestic formularies. Modest top-line gains from younger specialty products keep overall corporate net earnings stable but muted. |
| Q2 2027 | 392.80 | +1.78% | +1.85% | Initial Phase 3 MARITIME trial disclosures demonstrate viable monthly metabolic weight loss with manageable titration profiles. Relief over pipeline viability sparks institutional accumulation, partially offsetting ongoing European biosimilar price concessions. |
| Q3 2027 | 399.12 | +1.61% | +3.49% | Consistent free cash flow generation enables scheduled debt repayments, gradually improving interest coverage. Steady volume gains across Repatha and Tezspire help insulate operating profitability against wider macroeconomic monetary tightness. |
| Q4 2027 | 408.18 | +2.27% | +5.84% | Comprehensive registrational data disclosures de-risk metabolic filing timelines. A scheduled step-down in Horizon intangible amortization improves reported earnings, supporting positive sentiment and measured equity multiple stabilization into year-end. |
| Q1 2028 | 413.43 | +1.29% | +7.20% | Formal regulatory submissions for MariTide progress alongside steady international rare-disease expansion. Solid operational cash conversion cushions elevated clinical development spending, keeping quarterly net income on a dependable footing. |
| Q2 2028 | 423.35 | +2.40% | +9.77% | Expansion in oncology indications, notably Imdelltra, diversifies high-margin specialty revenue. Continuing debt reduction lowers net leverage toward target parameters, reinforcing credit health and improving through-cycle valuation support. |
| Q3 2028 | 429.19 | +1.38% | +11.29% | Pre-launch commercial manufacturing investments for metabolic candidates elevate operating expenditures. Denosumab revenue erosion approaches a predictable baseline, allowing specialty volume compounding to become the dominant earnings driver. |
| Q4 2028 | 438.37 | +2.14% | +13.67% | Regulatory approval of MariTide for chronic weight management activates initial wholesale distribution stocking. Prescribers welcome once-monthly dosing options, triggering an initial commercial re-rating despite intense incumbent competitive rebate walls. |
| Q1 2029 | 444.90 | +1.49% | +15.36% | Commercial rollout commences with steady commercial payer coverage adoption. Heavy launch promotional spending and competitive pricing discounts in primary-care channels keep initial operating margin expansion measured rather than explosive. |
| Q2 2029 | 452.19 | +1.64% | +17.25% | Patient adherence data confirms commercial demand for extended monthly dosing intervals. Accelerating sales across orphan therapies and internal biosimilars comfortably outpace residual mature-product decay, driving solid quarterly revenue expansion. |
| Q3 2029 | 459.90 | +1.70% | +19.25% | Further amortization step-downs mechanically lift reported net income toward underlying operating cash levels. Stable macroeconomic conditions and dependable free cash conversion attract defensive value allocations to common shares. |
| Q4 2029 | 466.71 | +1.48% | +21.02% | International regulatory approvals expand global distribution scale for newer metabolic and oncology assets. Annual free cash flow approaches eleven billion dollars, prompting management to evaluate renewed share repurchase capacity. |
| Q1 2030 | 473.06 | +1.36% | +22.67% | First-quarter results reflect robust organic volume growth across specialized franchises, fully overcoming historical denosumab patent losses. Net leverage normalization lowers borrowing costs, bolstering per-share equity earnings growth. |
| Q2 2030 | 478.32 | +1.11% | +24.03% | Class-wide pricing competition from emerging oral metabolic therapies moderates realized net unit realizations. Amgen's automated biomanufacturing scale defends operating margins, preserving steady mid-single-digit consolidated profit compounding. |
| Q3 2030 | 484.70 | +1.33% | +25.68% | Long-term cardiovascular outcomes trial data broaden metabolic label indications and improve insurance reimbursement access. Sustained cash collection supports continued progressive dividend compounding and balance-sheet fortifying. |
| Q4 2030 | 493.04 | +1.72% | +27.85% | Management resumes opportunistic common share repurchases as balance-sheet leverage reaches pre-acquisition benchmarks. Lower diluted share counts enhance earnings per share, driving constructive fourth-quarter performance. |
| Q1 2031 | 496.97 | +0.80% | +28.87% | Terminal exclusivity shifts across legacy immunology blockbusters generate transient headline noise. However, broad diversification across rare-disease, cardiovascular, and metabolic lines insulates consolidated corporate cash flow. |
| Q2 2031 | 504.88 | +1.59% | +30.92% | Next-generation bispecific oncology and autoimmune candidates advance into pivotal clinical testing. High recurring operational cash flow protects valuation multiples from late-cycle macroeconomic growth fluctuations. |
| Q3 2031 | 512.08 | +1.43% | +32.78% | The five-year transformation culminates with Amgen operating as a fully de-leveraged, high-margin biopharmaceutical leader. Durable orphan drug cash flows and metabolic revenues anchor long-term intrinsic compounding. |
Amgen's investment thesis centers on an operational race between structural patent attrition and specialized volume compounding. The base case establishes that six growth drivers—spearheaded by Repatha, Evenity, Tezspire, and Horizon orphan therapeutics—generate twenty-six percent volume growth, comprising seventy percent of product sales and insulating gross revenue against denosumab biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and Medicare price caps. Valuation sensitivity remains acutely tied to the cost of capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry. Carrying over fifty billion dollars in debt amid elevated benchmark yields caps forward price-to-earnings multiples near seventeen times forward non-GAAP earnings, as scheduled amortization runoff converges reported figures with cash realities. The primary counterargument warns that aggressive incretin rebate walls and tolerability-driven dropouts could turn pipeline assets into modest commercial contributors rather than transformative blockbusters.
Key insights
- Scheduled intangible amortization runoffs mechanically compress headline price-to-earnings multiples from twenty-four times toward seventeen times without requiring operational margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry.
- Operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry exceeding ten billion dollars annually prioritizes balance-sheet deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry over share buybacks, systematically converting enterprise valueenterprise valueA measure of total business value, commonly calculated as equity value plus debt and preferred claims, less cash and cash equivalents.View full glossary entry into per-share equity value.
- Counter-cyclical internal biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and orphan rare-disease monopolies insulate cash conversion from broader statutory price negotiation and primary-care payer rebate pressure.
Amgen is navigating a major changing of the guard. Older blockbuster medicines like Prolia and Enbrel face steep revenue losses from cheaper biosimilar copies and government price caps. However, Amgen's newer medicines for heart disease, severe asthma, and rare conditions are growing rapidly, bringing in over ten billion dollars in dependable annual cash flow. While the company must dedicate significant cash toward paying down debt rather than buying back shares, its diversified drug portfolio provides dependable financial stability.
Key insights
- Newer treatments for cholesterol, bone health, and rare diseases are expanding fast enough to replace fading older blockbusters.
- Over ten billion dollars in steady annual cash flow ensures reliable debt paydown and protects ongoing dividend payments.
- Heavy competition in obesity medicines and high interest rates mean investment gains will come from steady earnings, not hype.
Deep Dive
The market crowd views Amgen through an oversimplified binary lens: either a declining dividend utility crippled by denosumab patent expiries and fifty billion dollars in acquisition debt, or an emergent obesity titan destined to effortlessly claim market share with MariTide. Consensus models anchor heavily on headline patent erosion while assuming speculative incretin cash flows will arrive without commercial friction.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? The market crowd views Amgen through an oversimplified binary lens: either a declining dividend utility crippled by denosumab patent expiries and fifty billion dollars in acquisition debt, or an emergent obesity titan destined to effortlessly claim market share with MariTide. Consensus models anchor heavily on headline patent erosion while assuming speculative incretin cash flows will arrive without commercial friction.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value by fixating on headline patent cliffs while missing the underlying compounding engine. Amgen's six core growth drivers already represent nearly seventy percent of sales, compounding at twenty-six percent and generating over ten billion dollars in annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. This volume momentum replaces legacy revenue loss organically. Furthermore, mechanical runoff of Horizon amortization will compress trailing GAAP multiples toward forward cash realities, creating an underappreciated earnings floor.
Repricing Catalyst
What could make the market recognize and close that gap? Pivotal Phase 3 MARITIME clinical readouts and initial post-patent denosumab guidance in 2027 represent the decisive trigger. Demonstrating competitive monthly weight maintenance alongside volume-driven top-line stability across Repatha and Uplizna will force analysts to dismantle patent-cliff collapse models, re-underwriting Amgen as a durable specialty compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment diverges between value-oriented observers cautious of elevated multiples and debt burdens, and growth optimists pricing speculative incretin commercialization. Resolving Phase 3 tolerability data and observing debt paydown velocity will dictate whether sentiment transitions toward momentum or contraction.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive policy rates and elevated benchmark Treasury yields is a distinct headwind for Amgen's debt-heavy balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry. Higher refinancing rates increase debt-servicing friction on fifty-plus billion dollars of obligations and compress equity valuation multiples. However, highly inelastic healthcare demand and ten billion dollars in free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry provide superior defensive earnings resilience.
Advisor Disagreement
What do our AI Advisors disagree about most? The central disagreement across research reports concerns whether pipeline execution and orphan-drug volume can fully overcome simultaneous patent cliffs and high leverage. Optimistic analyses model MariTide capturing a major share of the global obesity market, driving operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above forty percent. Conversely, skeptical assessments emphasize that denosumab biosimilar cannibalization and Medicare price negotiations will strip billions in high-margin cash flow before pipeline assets scale, while elevated refinancing rates on fifty billion dollars of debt constrain buybacks. Observing Phase 3 discontinuation rates and quarterly gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry stabilization through 2027 will definitively resolve this debate.
Base-Case Forces
Event Risk ScoreLow33/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Commercial growth engine outruns patent erosion | Competitive Positioning | +22% | +26% | Six core commercial pillars—led by Repatha, Evenity, Tezspire, and Uplizna—generate twenty-six percent year-over-year volume growth and account for nearly seventy percent of product revenue. This broad-based momentum reliably absorbs impending denosumab biosimilar revenue losses, protecting baseline operating cash generation across the five-year forecast horizon. |
| MariTide monthly metabolic commercial launch | Innovation And Product | +20% | +24% | Pivotal Phase 3 MARITIME trials validate a differentiated once-monthly or bimonthly antibody-peptide mechanism for chronic weight management. Extended dosing intervals address major patient compliance bottlenecks in incretin therapies. Securing commercial approval unlocks high-margin revenue streams that drive durable operating earnings growth and terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry expansion. |
| Horizon rare disease integration and cash extraction | Operational Efficiency | +14% | +17% | Acquired rare-disease assets, including Tepezza, Uplizna, and Krystexxa, deliver non-discretionary revenue streams characterized by zero demand elasticity and strong gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry. Global commercial rollout and subcutaneous delivery reformulations expand international patient cohorts, generating highly predictable operating cash flows insulated from primary-care formulary rebate wars. |
| Post acquisition deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry restores capital returncapital returnCash or value distributed to investors, commonly through dividends, share repurchases, or return-of-capital payments.View full glossary entry | Capital Allocation | +11% | +12% | Annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry exceeding ten billion dollars enables systematic retirement of Horizon acquisition debt, lowering annual interest expenses by hundreds of millions of dollars. Normalizing balance-sheet leverage toward investment-grade targets improves credit metrics, paving the way for progressive dividend growth and eventual share repurchase reauthorization. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Denosumab biosimilar patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry erosion | Competitive Positioning | -17% | -20% | Loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry on Prolia and Xgeva unleashes multi-competitor biosimilar launches across domestic and international markets, driving franchise revenue down thirty to forty percent. This rapid pricing and volume deflation permanently eliminates billions in high-margin operating profit, creating a mechanical drag on consolidated top-line growth. |
| Medicare statutory drug price negotiation compression | Regulatory | -13% | -15% | Implementation of Inflation Reduction Act Maximum Fair Price mandates enforces steep statutory price discounts on mature blockbusters like Enbrel. Mandatory government discounting compresses gross-to-net realizations and triggers spillover rebate concessions into commercial insurance formularies, permanently capping domestic pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry on key established therapeutics. |
| Incretin market competitive crowding and discounting | Sector And Industry | -10% | -9.0% | Entrenched pharmaceutical duopolies and emerging oral incretin alternatives fiercely contest metabolic market share through aggressive formulary rebates and scaled manufacturing. MariTide faces substantial contracting barriers and gross-to-net discounting, capping ultimate commercial net price realization below initial peak-sales market expectations. |
| Elevated debt servicing under restrictive monetary policy | Macroeconomic And Macrofinancial | -8.0% | -9.0% | Carrying over fifty billion dollars in gross debt in an elevated interest-rate environment imposes significant carrying costs. Refinancing low-coupon legacy notes at prevailing yields elevates debt-servicing expense, absorbing operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry that would otherwise fund discretionary capital returnscapital returnsDistributions of capital to investors, commonly through dividends or share repurchases.View full glossary entry and suppressing valuation multiples. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| MariTide Phase 3 tolerability failure | 28% | -25% | Pivotal MARITIME readouts reveal severe gastrointestinal toxicities and patient discontinuation rates exceeding twenty percent despite dose titration. Eliminating Amgen's primary metabolic growth narrative destroys its valuation premium, triggering immediate multiple contraction back toward low-growth legacy pharmaceutical baselines. |
| Aggressive legislative expansion of price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry | 25% | -20% | Federal legislation expands Medicare price-setting to physician-administered Part B biologics while invalidating defensive patent thickets. Mandatory price cuts sweep across core oncology and cardiovascular portfolios, stripping billions in operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry and threatening balance-sheet deleveragingdeleveragingThe process of reducing total debt and leverage to strengthen financial stability.View full glossary entry schedules. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| MariTide superior cardiovascular outcomes label | 35% | +28% | Registrational Phase 3 trials demonstrate statistically superior reduction in major adverse cardiovascular events alongside pristine monthly tolerability. Commercial and Medicare payers mandate preferred first-line coverage, propelling peak annual sales beyond ten billion dollars and prompting aggressive institutional multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Oncology bispecific BiTE solid tumor breakthrough | 28% | +20% | Accelerated registrational trial readouts expand bispecific T-cell engager therapies, spearheaded by Imdelltra, into frontline solid tumors including lung and prostate malignancies. This technological validation unlocks unforecasted high-margin oncology revenue, expanding gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and re-rating corporate research productivity. |
Company Financial Analysis
Amgen Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Amgen's recent earnings tell a story of commercial resilience overcoming regulatory and generic headwinds. Total revenue reached $38.1 billion over the trailing twelve months, powered by nearly ten percent growth in the second quarter of 2026. Rapid double-digit volume expansion in newer treatments like Repatha and rare-disease therapies from the Horizon acquisition successfully offset a thirty-three percent drop in older bone-health drugs facing biosimilar competition. Reported GAAP net income surged to $12.65 billion on an operating basis, though headline growth was magnified by declining acquisition-related accounting amortization rather than pure operational improvement. More importantly, underlying free cash flow remained exceptionally sturdy at $10.18 billion, proving that Amgen generates dependable cash to manage patent expirations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 36.7B | USD 7.7B | USD 8.1B |
| 2024 | USD 33.4B | USD 4.1B | USD 10.4B |
| 2023 | USD 28.2B | USD 6.7B | USD 7.4B |
| 2022 | USD 26.3B | USD 6.6B | USD 8.8B |
| 2021 | USD 26B | USD 5.9B | USD 8.4B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 23.0x | TTM | Native | USD / USD |
| 2024 | 34.5x | TTM | Native | USD / USD |
| 2023 | 23.2x | TTM | Native | USD / USD |
| 2022 | 21.6x | Annual | Native | USD / USD |
| 2021 | 21.6x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability margins staged a strong recovery following the initial digestion of the Horizon merger. Gross margins rebounded to 70.8% in 2025 as inventory write-ups rolled off, while GAAP operating margins climbed to 36.8% in the second quarter of 2026. Synergies from specialized sales forces and strict administrative overhead control drove this operational rebound. Beneath the surface, non-GAAP operating margins held steady near 48.4%. While biosimilar competition against Prolia and mandatory Medicare discounts on Enbrel exert downward pressure on legacy lines, shifting product mix toward high-margin rare-disease treatments and manufacturing efficiencies should keep consolidated margins structurally healthy over the medium term.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 10.7B | 29.1% | 21.0% |
| 2024 | USD 7.3B | 21.7% | 12.2% |
| 2023 | USD 7.9B | 28.0% | 23.8% |
| 2022 | USD 9.6B | 36.3% | 24.9% |
| 2021 | USD 7.6B | 29.4% | 22.7% |
Balance sheet and leverage
AI Review
Amgen's balance sheet continues to digest the $27.8 billion acquisition of Horizon Therapeutics, carrying approximately $51.9 billion to $57.3 billion in gross debt against $14.0 billion in liquid cash reserves. While debt-to-equity remains elevated at 6.31, strong operating earnings support an interest coverage ratio above 4.2 times, ensuring solid debt-service capacity. Management has demonstrated commendable capital discipline by halting share repurchases to focus excess cash on retiring senior notes. In an elevated interest rate environment where refinancing carries higher coupons, paying down debt protects credit ratings and steadily transfers enterprise value into equity value for shareholders.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 54.6B | USD 9.1B | USD 45.5B net debt | 1.14x |
| 2024 | USD 60.1B | USD 12B | USD 48.1B net debt | 1.26x |
| 2023 | USD 64.6B | USD 10.9B | USD 53.7B net debt | 1.65x |
| 2022 | USD 38.9B | USD 9.3B | USD 31.3B net debt | 1.41x |
| 2021 | USD 33.3B | USD 8B | USD 25.3B net debt | 1.59x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Amgen operates a capital-efficient business model, keeping physical capital expenditures around five percent of revenue, or roughly $1.86 billion to $2.6 billion annually. These funds support advanced, continuous biomanufacturing facilities in Ohio and North Carolina, securing low unit costs and preventing supply bottlenecks for upcoming biologics. In contrast, research and development spending rose aggressively to nearly $7.0 billion, absorbing almost nineteen percent of revenue. This capital intensity reflects the extensive Phase 3 clinical trial program for MariTide across obesity, diabetes, and cardiovascular indications. Management is intentionally directing resources toward proprietary clinical assets to build high-margin replacement revenue for expiring blockbusters.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 1.9B | USD 7B |
| 2024 | USD 1.1B | USD 6B |
| 2023 | USD 1.1B | USD 4.8B |
| 2022 | USD 936M | USD 4.4B |
| 2021 | USD 880M | USD 6.3B |
Quarterly Forecast Scenarios
Amgen Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $374.08 | $386.48 | $393.36 | $750.26 | |
| $355.38 | $385.78 | $416.96 | $736.44 | |
| $334.05 | $392.18 | $429.47 | $743.40 | |
| $324.03 | $398.53 | $446.65 | $755.15 | |
| $327.27 | $407.95 | $455.71 | $776.22 | |
| $321.17 | $413.71 | $473.94 | $787.13 | |
| $317.96 | $423.80 | $488.16 | $802.83 | |
| $327.49 | $430.19 | $507.40 | $812.05 | |
| $320.94 | $439.79 | $517.55 | $839.18 | |
| $320.94 | $446.67 | $533.08 | $850.50 | |
| $324.15 | $454.16 | $554.40 | $872.39 | |
| $330.64 | $461.86 | $571.03 | $885.51 | |
| $337.25 | $468.78 | $576.74 | $909.56 | |
| $340.62 | $475.35 | $594.04 | $916.13 | |
| $337.22 | $480.87 | $605.92 | $936.51 | |
| $343.96 | $487.46 | $624.10 | $947.34 | |
| $347.40 | $495.84 | $630.34 | $969.59 | |
| $350.87 | $500.01 | $642.95 | $979.99 | |
| $357.89 | $507.87 | $655.81 | $999.60 | |
| $361.47 | $515.23 | $668.92 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported common pattern confirms that Amgen's underlying business is not stagnating, but undergoing an operational rotation. Six key growth drivers—spearheaded by Repatha, Evenity, Tezspire, and Horizon orphan assets—are expanding at twenty-six percent annually and represent nearly seventy percent of product sales, generating over ten billion dollars in annual free cash flow. This operational reality firmly refutes extreme collapse theses. Conversely, reports projecting rapid multiple expansion above twenty-five times forward earnings rely on correlated, overly optimistic assumptions regarding MariTide trial execution and frictionless obesity commercialization against entrenched giants. The strongest contrarian critique rightly emphasizes that imminent denosumab biosimilars and Inflation Reduction Act price caps strip high-margin legacy cash flows just as elevated benchmark interest rates elevate debt servicing on fifty-plus billion dollars of gross obligations. Relative weights prioritize evidence-grounded frameworks that balance core specialty volume resilience against legitimate patent-cliff headwinds and scheduled acquisition amortization runoff.
Universal Investor AI
The Polymath
GPT-6 AstraDelivers rigorous primary-source accounting verification, distinguishing non-cash acquisition amortization runoff from operating cash flows, while tracking IMDELLTRA clinical milestones. The analysis maintains balanced skepticism regarding pipeline optionality and valuation sensitivity in a high-yield macroeconomic regime.
Universal Investor AI
The Polymath
Opus 5Presents strong empirical rigor by demonstrating that six growth pillars generate seventy percent of product revenue. It astutely models the mechanical step-down in intangible amortization, providing an objective bridge between GAAP multiples and underlying cash-generative compounding power.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashOffers valuable legal insight into patent thicket litigation and staggered BPCIA denosumab settlements that delay volume erosion. However, its long-term equity appreciation path relies on highly optimistic clinical execution and multiple expansion across crowded metabolic indications.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashConstructs an extensive analysis of continuous biomanufacturing scale and multi-product volume expansion. Nevertheless, it projects aggressive top-line acceleration through 2031 that partially minimizes competitive incretin pricing pressure and persistent mandatory Medicare Part D statutory discounts.
Universal Investor AI
The Polymath
Gemini 3.8 FlashBalances commercial volume expansion across non-incretin drivers against imminent denosumab erosion and post-merger debt obligations. It appropriately identifies valuation multiple compression as the base case while acknowledging robust underlying free cash conversion exceeding ten billion dollars.
Universal Investor AI
The Polymath
Gemini 3.8 FlashDetails how rapid twenty-six percent volume expansion across core specialty pillars counteracts patent cliffs. However, its scenario path predicts an exceptionally rapid seventy percent share price gain that discounts competitive incretin price wars and potential tax dispute liabilities.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThoroughly investigates the operational cash waterfall, demonstrating how core growth drivers insulate gross profit from Medicare price cuts. It maintains realistic expectations on debt amortization timing, though its pipeline catalyst timing remains somewhat front-loaded.
Michael Burry AI
The Vulture
Gemini 3.8 FlashConstructs a potent contrarian critique emphasizing immediate denosumab biosimilar cannibalization, Enbrel Medicare cuts, and high refinancing hurdles. While its downside target is overly punitive given proven orphan-drug cash generation, its friction modeling enforces essential valuation discipline.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashAccurately identifies the valuation tension between speculative metabolic expectations and mature portfolio attrition under tight monetary policy. It correctly penalizes starting valuation multiples, though it somewhat overlooks Amgen's proven internal biosimilar manufacturing cash conversion.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashProvides a disciplined fundamental accounting perspective on trailing valuation multiples, high interest rate drag, and denosumab patent cliffs. However, it somewhat discounts the commercial momentum of newly integrated rare-disease revenue and volume resilience across core cardiovascular franchises.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashGrounds valuation in tangible owner cash flows and details how volume growth in newer therapies offsets off-patent decay. It appropriately highlights lack of near-term safety margin, though it slightly underweights international commercialization velocity across rare-disease assets.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashEffectively captures operational leverage and aggressive biomanufacturing infrastructure advantages across biosimilars and rare diseases. However, its forecast trajectory assumes rapid institutional multiple re-rating that downplays sticky debt carrying costs and competitor incretin manufacturing scale.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashApplies a sound macro-cycle lens to corporate deleveraging, balance-sheet resilience, and non-cyclical healthcare demand. While its long-term framework is robust, it relies heavily on frictionless subcutaneous formulation rollouts to defend segment operating profitability.
Elon Musk AI
The Visionary
Gemini 3.8 FlashPresents a rigorous contrarian case examining GIP-antagonism biological trade-offs, titration challenges, and steep loss-of-exclusivity arithmetic. However, its severe projected multi-year drawdown understates the structural earnings floor provided by durable rare-disease and cardiovascular cash flows.
Research Provenance
References & Context
This Amgen consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 75 deduplicated sources retained for this batch.
- 01Fact Sheet: Medicare Drug Price Negotiation Program June 2023cms.gov
- 02Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026cms.gov
- 03AMGEN INC - Form 10-Q - FY2026sec.gov
- 04AMGEN INC - Form 10-Q - FY2026sec.gov
- 05amgen reports first quarter 2026 financial resultssec.gov
- 06amgn-20260630sec.gov
- 07Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
- 08Amgen Inc Earnings - Analysis & Highlights for Q2 2026alpha-sense.com
- 09AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS| Amgenamgen.com
- 10IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgenamgen.com
- 11RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS| Amgenamgen.com
- 12AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR | Amgen Inc.amgen.gcs-web.com
- 13MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes | Applied Clinical Trials Onlineappliedclinicaltrialsonline.com
- 14Amgen (AMGN) Stock Analysis — Quality Score & Fair Valuebeanvest.com
- 15Amgen SWOT Analysis – businessmodelcanvastemplate.combusinessmodelcanvastemplate.com
And 60 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.